1Westerhof GR, Rijnboutt S, Schornagel JH, et al. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-1 cells expressing folate-binding protein [ J]. Cancer Res, 1995, 55(17) : 3795-3802.
2Seidel H, Nvqaard R, Moe PJ, et al. On the prognostic value of systemic mcthotrexate clearance in childhood acute lymphoblastic leukemia [J]. Leuk Res, 1997, 21(5): 429- 434.
3Chu E, Allegra CJ, Antifolates Z, et al. Cancer chemotherapy and biotherapy: principle and practice [ M ]. Philadelphia: Lippineot-Raven, 1996: 109-148.
4Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastie leukemia [J]. J Clin Invest, 1994, 94(5) : 1996-2001.
5Freeman A1, Weinberg V, Breeher ML, et al. Comparison of intermediate dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children [J]. N Engl J Med, 1983, 308(9) : 477-484.
6Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect [J]. N Engl J Med, 1986, 314(8) : 471-477.
8Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM90. German-Austrian-Swiss ALL-BFM Study Group [J]. Blood, 2000, 95(11): 3310-3322.
9Peiter A, Seherappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients, results and conclusions of the multicenter trial, ALL-BFM86 [J]. Blood, 1994, 84(9) : 3122-3133.
10Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children [J]. Blood, 1994, 84(2) : 355-366.
2Odoul F, Leguellec C,Lamagnere JP,et al. Prediction of methotrexateelimination after high dose infusion in children with acute lymphoblastic leukemia using a population pharmacokinetic approach. Fundam Clin Parmacol, 1999, 13: 595-604.
3Rask C, Albert F, Bentzen SM, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.Acta Oncol,1998, 37: 277-284.
4Galpin AJ,Schuetz JD, Masson E, et al. Differences in folypolyglutamatate synthetase and dihydrofolate reductase expression in human Blineage versus T-lineage lymphoblastic leukemia: mechanisms for lineage difference in methotrexate polyglutamylation and cytotoxicity.Mol Pharmacol, 1997, 52: 155-163.
5Pindel D,Woo S.Prevention and treatment of meningeal leukemia in children[J].Blood,1994,84(4):335.
6Reiter A,Schrappe M,Ludwig WD,et al.Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients,results and conclusion of the multicenter trial ALL-BFM 86[J].Blood,1994,84(9):3122-3127.
7Pearson AD,Amineddine HA,Yule M,et al.The influence of serum methotrexate concentrations and drug dosage in outcome in childhood acute lymphoblastic leukemia[J].Br J Cancer,1991,64(1):169.
8Masson E,Relling MV,Synold TW,et al.Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo:a rationale for high-dose methotrexate[J].J Clin Invest,1996,97:73-80.
9Seidel HN,Moe R,Jaoobsen PJ,et al.On the prognostic value of systemic methotrexate clearance in childhood acute lymphoblastic leukemia[J].Leuk Res,1997,21 (5:) 429.
10Enans WF,Relling MV,Boyett JM,et al.Dose pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia:what can we learn from small studies?[J].Leuk Res,1997,21 (5):435.
